Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-497 in acute upper respiratory infection and acute bronchitis
NCT03726853Phase 2Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- May 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CKD-497 in acute upper respiratory infection (URI) and acute bronchitis (4 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Bronchitis Severity Score at 1 week and The 8-symptom related questions in the Daily Cough and Phlegm at 1 week. Started May 2018; status: completed.
02
Drugs
CKD-497
03
Conditions
acute upper respiratory infection (URI)acute bronchitis
Beyond the preview
Go deeper on NCT03726853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03726853.